This group has a normal urine status on admission to hospital. Abnormal urine status is defined anuric OR as 2* or more of the following findings:
urine osmolarity below normal values
leukozyturia
hematuria
albuminuria/ proteinuria * if urine is positive for nitrite or bacteria, abnormal urine status is defined as 3 or more of the findings.

This group has an abnormal urine status on admission to hospital WITHOUT serum-albumin below 2.0 g/dl AND WITHOUT antithrombin III level below 70%.

This group has an abnormal urine status on admission to hospital PLUS serum-albumin below 2.0 g/dl OR antithrombin III level below 70%.

Covid-19

University Medical Center Goettingen

Predict Adverse Events by Covid-19 Nephritis

Covid-19 Associated Nephritis as Early Predictor for Complicated Course of Disease

Time (in days) from hospital admission to transferral to ICU (ICU level high) OR time (in days) from Hospital Admission to Death

Number of Complications are defined as
Need of transferral to "ICU low" (ICU level 1)*
Need of transferral to "ICU high" (ICU level 3)*
Need of mechanical ventilation* OR
Need for renal replacement therapy* OR
Need of extracorporeal membrane oxygenation* OR
Death * in the first 10 days after admission to hospital

Time on "ICU low" (in days),
Time on "ICU high" (in days),
Time on invasive mechanical ventilation (in days)
Time on extracorporeal membrane oxygenation (in days)
Time on renal replacement therapy (in days)

lowest serum-albumin
lowest antithrombin III

Quesionnaires will be faxed to principal investigator and be analyzed by the department of medical statistics.

Prof. Dr. O. Gross

Professor

University Hospital Goettingen

Universitätsklinikum Hamburg-Eppendorf

University Hospital, Aachen

Transplantationszentrum Köln-Merheim

Placebo drug that simulates Irbesartan tablets 150mg /qd, oral dosing; HuangKui Capsule 2.5g/tid, oral dosing

Placebo drug that simulates Irbesartan tablets 150mg /qd, oral dosing; HuangKui Capsule 2.5g/tid, oral dosing irbesartan tablets 150mg /qd, oral dosing; Placebo drug that simulates HuangKui capsule 2.5g/tid, oral dosing

irbesartan tablets 150mg /qd, oral dosing HuangKui Capsule 2.5g/tid, oral dosing.

Diabetic Kidney Disease

Placebo drug that simulates Irbesartan tablets 150mg /qd, oral dosing

Placebo drug that simulates Irbesartan tablets

irbesartan tablets 150mg /qd, oral dosing

irbesartan tablets

Placebo drug that simulates HuangKui capsule 2.5g/tid, oral dosing

Placebo drug that simulates HuangKui capsule

HuangKui Capsule

Jiangsu Province Hospital of TCM

Clinical Trial of HuangKui Capsule to Treat Diabetic Kidney Disease

A Randomized, Double-blind, Parallel-controlled, Multi-center Clinical Trial of HuangKui Capsule to Treat Diabetic Kidney Disease

ACR baseline changes and changes in the rate

24-hour urinary protein quantification baseline changes and changes in the rate

Glomerular filtration rate (eGFR) baseline changes

Changes and the rate change before and after treatment.

High sensitivity C - reactive protein baseline values

Jiangsu Famous Medical Technology Co., Ltd.

10 patients with hemochromatosis treated with Deferasirox

10 patients with hemochromatosis treated with venesection

20 patients with myelodysplastic syndrome treated with Deferasirox

10 healthy control persons to assess the normal level of investigational blood tests.

Hemochromatosis

Myelodysplastic Syndromes

Deferasirox tablets ( 250 mg or 500 mg) dispersed in a drinkable solution, 10 mg/kg/day, once daily for 12 months

Deferasirox

Treated with venesection every 8-10 day for 12 months, or until serum-ferritin has been reduced to about 50 µg/L.

Venesection

Deferasirox tablets ( 250 mg or 500 mg) dispersed in a drinkable solution starting with 10 mg/kg/day, once daily for 2 weeks and thereafter 20 mg/kg/day for 11,5 months.

Haukeland University Hospital, Clinical Trial Unit

Treatment of Iron Overload With Deferasirox (Exjade) in Hereditary Hemochromatosis and Myelodysplastic Syndrome

Deferasirox Versus Venesection in Patients With Hemochromatosis and for Treatment of Transfusional Siderosis in Myelodysplastic Syndrome: Diagnostics and New Biomarkers.

Cu,Zn-Super Oxid Dismutase (SOD)is an antioxidant enzyme

nephritis/turvotus

Predict Adverse Events by Covid-19 Nephritis

Clinical Trial of HuangKui Capsule to Treat Diabetic Kidney Disease

Treatment of Iron Overload With Deferasirox (Exjade) in Hereditary Hemochromatosis and Myelodysplastic Syndrome

Plasma and Abscess Fluid Pharmacokinetics of Cefpirome and Moxifloxacin After Single and Multiple Dose Administration

Täydellisin lääketieteellinen tietokanta tieteen tukemana